Bevacizumab in combination with chemotherapy for the second line treatment of HER2 negative metastatic breast cancer [ID488]

  • Discontinued
  • GID-TAG432

Documents

Documents created during the development process.

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line): appendix B - draft scope for consultation (pre-referral) May 2011

Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line): appendix C - provisional matrix (pre-referral) May 2011